Available Technology

Immunotoxin with in-vivo T cell Suppressant Activity

The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. The toxin portion of the immunotoxin is genetically engineered to maintain bioactivity when recombinantly produced inPichia pastoris. Data are available in transgenic animals expressing human CD3epsilon which supports the effects of the immunotoxin against T cells.
Abstract: 
The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. The toxin portion of the immunotoxin is genetically engineered to maintain bioactivity when recombinantly produced inPichia pastoris. Data are available in transgenic animals expressing human CD3epsilon which supports the effects of the immunotoxin against T cells.
Benefits: 
Specificity of the immunotoxin avoids the killing of non-T cells, reducing side-effects associated with other mechanisms of treatment (e.g., radiation and cyclophosphamide) such as infection and induced malignancy. -A GMP production process has already been successfully implemented, and patient doses are available. -All testing required for an FDA issued IND has been completed, allowing faster evaluation of the efficacy of the invention.
applications: 
Inventors: 
David Neville Jr
Patent Number: 
13/443,779 US Application No. 07/907,409 PCT Application No. PCT/US92/00813 US Application No. 60/039,987 PCT Application No. PCT/US98/04303 US Application No. 10/435,567 Foreign rights are also available.
Internal Laboratory Ref #: 
E-012-1991/0 Updated:Nov 9, 2015
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin